ROTHBLATT MARTINE A sold $4.7M of UTHR (indirect holdings)
ROTHBLATT MARTINE A (Chairperson & CEO) sold 9,500 indirectly-held shares of UNITED THERAPEUTICS Corp (UTHR) at an average of $494.79 ($492.91–$498.25, $4.70M total) across 6 trades on 2026-09-18 under a Rule 10b5-1 trading plan.
How this was made
The 30-second read
Why it matters
The $4.7M sale reduces insider ownership but leaves the CEO with a substantial stake, suggesting continued confidence.
Market read
Primary insider sale news; modest short‑term trading relevance.
What to watch
Rothblatt's 10b5‑1 plan may have been set months ago; the sale does not reflect current sentiment.
Background
Form 4 filings disclose insider transactions; a sale by a CEO is closely watched by investors.
Ticker impact
CEO Martine Rothblatt sold 9,500 shares for $4.7M via a 10b5‑1 plan, reducing her stake to 324,443 shares.
Possible modest downside of 2‑4% over the next few days as the market digests the sale.
A $4.7M sale by the chairperson is material but not large enough to trigger a major move; market typically reacts modestly to such insider disposals.
Market effects
Minimal impact on the biotech/biopharma sector; other companies unlikely to be affected.
U.S. market only; no regional ripple.
Low; the filing is company‑specific.
Counterpoint
The sale could be a routine liquidity event under a pre‑arranged plan, not a negative signal.
Key entities
- CompanyUnited Therapeutics Corp
Biopharma company developing organ transplantation and pulmonary therapies.
- ExecutiveMartine Rothblatt
Chairperson & CEO of United Therapeutics.
